These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37409941)

  • 21. LINC00240 sponges miR-4465 to promote proliferation, migration, and invasion of hepatocellular carcinoma cells via HGF/c-MET signaling pathway.
    Bu WJ; Fang Z; Li WL; Wang X; Dong MJ; Tao QY; Zhang L; Xu YQ
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10452-10461. PubMed ID: 33155201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis.
    Bozkaya G; Korhan P; Cokaklı M; Erdal E; Sağol O; Karademir S; Korch C; Atabey N
    Mol Cancer; 2012 Sep; 11():64. PubMed ID: 22962849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma.
    Charan M; Dravid P; Cam M; Audino A; Gross AC; Arnold MA; Roberts RD; Cripe TP; Pertsemlidis A; Houghton PJ; Cam H
    Int J Cancer; 2020 Jun; 146(11):3184-3195. PubMed ID: 31621900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resveratrol suppresses human hepatocellular carcinoma via targeting HGF-c-Met signaling pathway.
    Gao F; Deng G; Liu W; Zhou K; Li M
    Oncol Rep; 2017 Feb; 37(2):1203-1211. PubMed ID: 28075467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma.
    Ogunwobi OO; Puszyk W; Dong HJ; Liu C
    PLoS One; 2013; 8(5):e63765. PubMed ID: 23723997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma.
    Liu G; Rui W; Zheng H; Huang D; Yu F; Zhang Y; Dong J; Zhao X; Lin X
    Eur J Immunol; 2020 May; 50(5):712-724. PubMed ID: 31981231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-449a suppresses hepatocellular carcinoma cell growth via G1 phase arrest and the HGF/MET c-Met pathway.
    Cheng J; Wu LM; Deng XS; Wu J; Lv Z; Zhao HF; Yang Z; Ni Y
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):336-344. PubMed ID: 30108016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway.
    Tan S; Li R; Ding K; Lobie PE; Zhu T
    FEBS Lett; 2011 Jul; 585(14):2229-34. PubMed ID: 21658389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MACC1 suppresses cell apoptosis in hepatocellular carcinoma by targeting the HGF/c-MET/AKT pathway.
    Yao Y; Dou C; Lu Z; Zheng X; Liu Q
    Cell Physiol Biochem; 2015; 35(3):983-96. PubMed ID: 25660117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
    Wu X; Luo H; Shi B; Di S; Sun R; Su J; Liu Y; Li H; Jiang H; Li Z
    Mol Ther; 2019 Aug; 27(8):1483-1494. PubMed ID: 31078430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C7 peptide inhibits hepatocellular carcinoma metastasis by targeting the HGF/c-Met signaling pathway.
    Zhao M; Wang Y; Liu Y; Zhang W; Liu Y; Yang X; Cao Y; Wang S
    Cancer Biol Ther; 2019; 20(12):1430-1442. PubMed ID: 31441380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
    Fu R; Jiang S; Li J; Chen H; Zhang X
    Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival.
    Ang CS; Sun MY; Huitzil-Melendez DF; Chou JF; Capanu M; Jarnagin W; Fong Y; Dematteo RP; D'Angelica M; Allen P; Chen CT; O'Reilly EM; Weiser MR; Abou-Alfa GK
    Anticancer Res; 2013 Aug; 33(8):3241-5. PubMed ID: 23898085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma.
    Ueki T; Fujimoto J; Suzuki T; Yamamoto H; Okamoto E
    Hepatology; 1997 Apr; 25(4):862-6. PubMed ID: 9096589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges.
    Lu F; Ma XJ; Jin WL; Luo Y; Li X
    Front Immunol; 2021; 12():690565. PubMed ID: 34054880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
    Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
    Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.
    Steinway SN; Dang H; You H; Rountree CB; Ding W
    PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth.
    Luo T; Zhang SG; Zhu LF; Zhang FX; Li W; Zhao K; Wen XX; Yu M; Zhan YQ; Chen H; Ge CH; Gao HY; Wang L; Yang XM; Li CY
    J Exp Clin Cancer Res; 2019 Mar; 38(1):130. PubMed ID: 30885237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.